Pharmacokinetics of paclitaxel and carboplatin in combination.

@article{Kearns1995PharmacokineticsOP,
  title={Pharmacokinetics of paclitaxel and carboplatin in combination.},
  author={Christine M. Kearns and Chandra Prakash Belani and Kadir Erkmen and Michael Zuhowski and D J Hiponia and D Zacharski and Christine Engstrom and Ramesh K. Ramanathan and M R Trenn and Joseph Aisner},
  journal={Seminars in oncology},
  year={1995},
  volume={22 5 Suppl 12},
  pages={1-4; discussion 5-7}
}
We studied the pharmacokinetics of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin administered in combination to 21 patients with advanced non-small cell lung cancer. Paclitaxel was administered as a 24-hour intravenous infusion at doses of 135 to 200 mg/m2. Carboplatin, dosed to a target area under the concentration-time curve of 5, 7, 9, or 11 mg/mL.min, was administered as a 20-minute infusion immediately following paclitaxel. Neither the paclitaxel… CONTINUE READING